CD4 and neoplasm: CD4+ effector T cells that were primed in TDLNs and stimulated with IL-7 and IL-23 inhibited tumor progression more strongly than those stimulated with IL-2 and IL-7 when they were transferred into lymphopenic tumor-bearing mice.